Keytruda works differently from chemotherapy. Rather than attacking every fast-dividing cell, it releases your own immune T-cells to find and destroy cancer. That targeted approach is often gentler day-to-day. In Turkey, the first trip usually lasts 1–2 weeks, from pathology review to your first infusion. JCI-accredited oncology centers, led by ESMO-certified specialists, confirm eligibility, set the schedule, and stay in touch after you go home.
How Do You Qualify for Keytruda? The Pre-Booking Biomarker Checklist
Whether Keytruda will help you is decided by a lab test. Some cancer cells protect themselves by using a protein called PD-1/PD-L1, which acts as a signal that turns off your immune cells before they can attack the tumor. A biomarker test on your tumor tissue checks if your cancer relies on this 'off signal' – showing whether Keytruda can block it and allow your immune system to fight the cancer.
PD-L1 scoring: TPS and CPS
PD-L1 is measured with the FDA-approved 22C3 test and reported as two scores. The Tumor Proportion Score (TPS) is the share of tumor cells that test positive. The Combined Positive Score (CPS) also counts nearby immune cells. For first-line single-agent Keytruda in advanced lung cancer, a TPS of at least 1% qualifies patients for treatment. A score of 50% or higher offers the strongest therapeutic benefit.
Two other ways to qualify: your tumor's DNA
PD-L1 is not the only route. Two others look at the DNA inside your tumor instead.
The first route is faulty DNA repair. Healthy cells fix copying errors every time they divide. Some tumors lose that repair system. Doctors call such a tumor mismatch repair deficient (dMMR), or microsatellite instability-high (MSI-H). Errors pile up, and the tumor cells end up looking clearly abnormal. Your immune system spots abnormal cells more easily, so these tumors respond to Keytruda more often. The FDA approved Keytruda for any advanced solid tumor with this profile. It applies once earlier treatment has stopped working.
The second route is a very high mutation count. Tumor mutational burden counts the mutations inside the tumor. Labs report it per megabase, meaning per million letters of DNA. Ten or more per megabase counts as high. The FDA approved Keytruda for these tumors too, again after earlier treatment has failed.
Both profiles are read from tumor tissue your doctors already have. A staining test shows whether the repair proteins are missing. Gene sequencing counts the mutations. Neither usually needs a new biopsy.
The main qualifying routes and their tests:
| Your situation | What the lab must show | Which test |
|---|---|---|
| Lung cancer, as your first treatment | PD-L1 TPS ≥1% (best ≥50%) | PD-L1 stain |
| Triple-negative breast, esophageal squamous cell | PD-L1 CPS ≥10 | PD-L1 stain |
| Stomach, cervical, head and neck squamous cell | PD-L1 CPS ≥1 | PD-L1 stain |
| Any advanced cancer, after earlier treatment | Faulty DNA repair (MSI-H or dMMR) | Staining test or gene sequencing |
| Any advanced cancer, after earlier treatment | 10 or more mutations per megabase (TMB-High) | Gene sequencing |
What to bring to your consultation
Bring your pathology and biopsy blocks, plus any PD-L1, MSI, or gene-sequencing reports. A Turkish oncologist can confirm eligibility from these remotely, before you arrange any travel.
Bookimed Expert Insight: use that first remote review to ask questions, not only to send files. In Bookimed reviews, patients praise one thing most often. The oncologist explains the immunotherapy plan and its side effects without rushing. ESMO-certified oncologists such as Yesim Yildirim and Seref Komurcu review your case before you commit.
How Is Keytruda Scheduled to Reduce Trips to Turkey?
Keytruda is a short infusion. Its schedule is more flexible than many patients expect. That matters when each cycle means a trip. These options come straight from the drug's FDA labeling and apply at any clinic, so ask which schedule yours offers.
IV schedules: Q3W vs Q6W
Two single-agent IV schedules are interchangeable: 200 mg every 3 weeks, or 400 mg every 6 weeks. The every-6-weeks option roughly halves the number of clinic visits. Each infusion takes about 30 minutes. When Keytruda is combined with chemotherapy, teams use the 200 mg every-3-weeks schedule.
Subcutaneous Keytruda Qlex
Keytruda also comes as a skin injection called Qlex, which pairs pembrolizumab with an enzyme that helps it absorb. The FDA approved it in September 2025 for every solid-tumor use already approved for the IV form. A nurse gives it in the thigh or abdomen in about 1–2 minutes. That cuts time in the treatment suite by up to half. In its trial, Qlex matched the IV drug's blood levels. Tumor shrinkage was comparable, too.
For a traveling patient, the three options weigh up differently:
| Option | Dose and interval | In clinic | Travel impact |
|---|---|---|---|
| Standard IV | 200 mg / 3 weeks | ~30 min | More frequent trips |
| Extended IV | 400 mg / 6 weeks | ~30 min | Half as many trips |
| Subcutaneous Qlex | Injection / 3 or 6 weeks | ~1–2 min | Shortest visit |
How long the full course runs
Course length depends on the goal. After surgery, it runs up to 12 months, about 18 doses. For advanced disease, it continues up to 24 months, around 35 cycles, or for as long as it keeps working. On single-agent maintenance, ask whether the every-6-weeks or subcutaneous option suits you. Either approach reduces the number of trips you need to plan to Turkey.
What Outcomes to Discuss With Your Oncologist by Cancer Type
There is no single success number for Keytruda. The benefit depends on your cancer type, its stage, and your biomarker status. That's exactly why the eligibility tests above matter so much.
How benefit is measured
Doctors judge Keytruda in two ways: how often tumors shrink, and how long that benefit lasts. In MSI-High or dMMR tumors, responses tend to be especially durable.
Cancer types with trial evidence
Pembrolizumab has been established in large clinical trials across several cancers. A Turkish oncologist can point to trial evidence for your tumor type. Ten-year survival with Keytruda in advanced melanoma was 34%, against 23.6% on the older immunotherapy. Added to chemotherapy, it increased five-year survival in advanced nonsquamous lung cancer by about 70% compared to chemotherapy alone. First-line pembrolizumab is established in squamous lung cancer as well.
Responses also last longer in MSI-High or dMMR colorectal cancer. Three years on, 76% of those who responded to Keytruda were still responding, against 24% on chemotherapy.
Why your outcome may differ
How Keytruda is used shifts with the goal. After surgery, the aim is to lower the chance the cancer returns. In advanced disease, it's long-term control while protecting your quality of life. The clearest next step is to ask the Turkish tumor board which regimen matches your profile. Centers such as Memorial Antalya Hospital follow the same NCCN and ESMO guidelines these trials sit within.
How Your Care Team Monitors and Manages Side Effects
Keytruda is generally easier to tolerate than chemotherapy, and most patients finish treatment without serious organ inflammation.
Potential Keytruda side effects
The effects patients ask about most involve inflammation of the lungs, bowel, liver, or hormone glands. The majority of patients on Keytruda avoid them. From your first cycle, your team has a plan for managing each of these effects.
These figures come from Keytruda's prescribing information, covering 2,799 patients treated with Keytruda alone.
| Possible effect | Patients who avoid it | If it occurs |
|---|---|---|
| Lung inflammation | about 96.6% | Keytruda paused, treated, resumed once settled |
| Bowel inflammation | about 98.3% | Keytruda paused and treated; clears in about 85% of cases |
| Liver inflammation | about 99.3% | Usually caught on routine blood tests before you feel it |
| Hormone-gland inflammation | about 99.4% | Simple hormone replacement if needed |
Your routine monitoring schedule
Your team runs the same checks for everyone. Baseline blood tests come first. Then pre-cycle liver enzymes, kidney function, and a thyroid panel run roughly every 6–8 weeks, per standard monitoring. This catches an early change before you'd notice it. Contraception is advised during treatment and for four to five months after the last dose. Anyone with active autoimmune disease or a past transplant gets extra review.
How effects are managed by grade
Management follows a simple grade-based plan. For mild symptoms, your doctor will monitor you closely while offering supportive care. For moderate symptoms, your care team will temporarily pause Keytruda and start a corticosteroid, such as prednisone (0.5–1.0 mg/kg daily), to calm the immune response. Treatment resumes once symptoms settle. Most inflammatory effects reverse fully when caught early. A few, such as an underactive thyroid, may need ongoing hormone replacement. JCI-accredited centers such as Hisar Hospital Intercontinental keep a coordinator reachable around the clock. Keep a symptom diary, and report any new rash, diarrhea, or fatigue early.
Is the Keytruda You Get in Turkey Genuine?
Turkey backs the Keytruda you receive with two national safeguards: an end-to-end track-and-trace registry, and enforced cold-chain storage. It's supplied directly from Merck (MSD), its manufacturer. The formulation and batch standards match the vials used in the US, UK, and Western Europe.
Turkey's ITS track-and-trace
Turkey was the first country in the world to run a full end-to-end drug track-and-trace system. It launched in 2012 under the national medicines agency. Every carton carries a unique 2D barcode: a global product number plus its own serial, batch, and expiry.
Each hand-off from importer to hospital ward is scanned and logged. A pack flagged as counterfeit or tampered is blocked in real time, so it can't reach a patient.
Cold-chain storage at 2–8 °C
Keytruda is a biologic that must stay between 2 and 8 degrees Celsius. Turkey enforces Good Distribution Practice. Hospital pharmacies use validated temperature monitoring that alerts staff if the range is ever broken.
Bookimed Expert Insight: ask the clinic to show you the factory-sealed, scanned vial and its batch number. Logged in the national system, that number ties your dose straight back to the manufacturer.
Continuing Care at Home: Shared Monitoring and Safe Travel
Immunotherapy doesn't end when you fly home, and Keytruda care in Turkey is built for that. Monitoring is shared, so it continues wherever you live.
Shared monitoring with your home team
JCI-accredited Turkish clinics coordinate with your GP or oncologist at home. You can complete your pre-cycle blood tests locally and share the results via telehealth. This allows your oncology team to review your safety markers and clear you for your next treatment session. Bookimed coordinators handle documents, communication with the clinic, and help with flight arrangements. Free interpreters are available at Bookimed partner centers for patients who need them.
Flying safely after an infusion
A first trip usually lasts 7–14 days: pathology review, imaging, and your first infusion. Patients wait 24–48 hours after an infusion before flying, when any early reaction is most likely. On the flight, lower the risk of clots with compression stockings, steady hydration, and a short walk each hour. Doctors generally want hemoglobin around 8 g/dL for flying, and medical clearance for very low platelets or untreated breathlessness.
What to carry
Keep these in your hand luggage:
- Original pathology reports and PET-CT or other scans.
- Clearly labeled medications in their original packaging.
- A translated clinical summary and Keytruda patient card with your dose and contacts.
- A signed travel-clearance letter from your oncologist.
Simple steps like a mask and hand hygiene help in transit, which the CDC advises for immunocompromised travelers. Agree your home monitoring and telehealth check-ins with both teams before your first trip.